Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
Seminars in Immunopathology
Published in: Seminars in Immunopathology 5/2016

01-09-2016 | Review

Regulatory roles of mast cells in immune responses

Authors: Hideaki Morita, Hirohisa Saito, Kenji Matsumoto, Susumu Nakae

Published in: Seminars in Immunopathology | Issue 5/2016

Login to get access

Abstract

Mast cells are important immune cells for host defense through activation of innate immunity (via toll-like receptors or complement receptors) and acquired immunity (via FcεRI). Conversely, mast cells also act as effector cells that exacerbate development of allergic or autoimmune disorders. Yet, several lines of evidence show that mast cells act as regulatory cells to suppress certain inflammatory diseases. Here, we review the mechanisms by which mast cells suppress diseases.
Literature
1.
Voehringer D (2013) Protective and pathological roles of mast cells and basophils. Nat Rev Immunol 13:362–375CrossRefPubMed
2.
Gurish MF, Bryce PJ, Tao H, Kisselgof AB, Thornton EM, Miller HR et al (2004) IgE enhances parasite clearance and regulates mast cell responses in mice infected with Trichinella spiralis. J Immunol 172:1139–1145CrossRefPubMed
3.
4.
Metz M, Grimbaldeston MA, Nakae S, Piliponsky AM, Tsai M, Galli SJ (2007) Mast cells in the promotion and limitation of chronic inflammation. Immunol Rev 217:304–328CrossRefPubMed
5.
El-Refaie AM, Burt AD (2005) Mast cells and c-Kit expression in liver allograft rejection. Histopathology 47:375–381CrossRefPubMed
6.
Goto E, Honjo S, Yamashita H, Shomori K, Adachi H, Ito H (2002) Mast cells in human allografted kidney: correlation with interstitial fibrosis. Clin Transplant 16(Suppl 8):7–11CrossRefPubMed
7.
Jungraithmayr W (2015) The putative role of mast cells in lung transplantation. Am J Transplant 15:594–600CrossRefPubMed
8.
Itoh S, Nakae S, Velotta JB, Kosuge H, Connolly A, Tsai M et al (2010) The role of recipient mast cells in acute and chronic cardiac allograft rejection in C57BL/6-KitW-sh/W-sh mice. J Heart Lung Transplant 29:401–409CrossRefPubMed
9.
Lu LF, Lind EF, Gondek DC, Bennett KA, Gleeson MW, Pino-Lagos K et al (2006) Mast cells are essential intermediaries in regulatory T-cell tolerance. Nature 442:997–1002CrossRefPubMed
10.
Hara M, Kingsley CI, Niimi M, Read S, Turvey SE, Bushell AR et al (2001) IL-10 is required for regulatory T cells to mediate tolerance to alloantigens in vivo. J Immunol 166:3789–3796CrossRefPubMed
11.
Townsend JM, Fallon GP, Matthews JD, Smith P, Jolin EH, McKenzie NA (2000) IL-9-deficient mice establish fundamental roles for IL-9 in pulmonary mastocytosis and goblet cell hyperplasia but not T cell development. Immunity 13:573–583CrossRefPubMed
12.
Hultner L, Druez C, Moeller J, Uyttenhove C, Schmitt E, Rude E et al (1990) Mast cell growth-enhancing activity (MEA) is structurally related and functionally identical to the novel mouse T cell growth factor P40/TCGFIII (interleukin 9). Eur J Immunol 20:1413–1416CrossRefPubMed
13.
Matsuzawa S, Sakashita K, Kinoshita T, Ito S, Yamashita T, Koike K (2003) IL-9 enhances the growth of human mast cell progenitors under stimulation with stem cell factor. J Immunol 170:3461–3467CrossRefPubMed
14.
Eller K, Wolf D, Huber JM, Metz M, Mayer G, McKenzie AN et al (2011) IL-9 production by regulatory T cells recruits mast cells that are essential for regulatory T cell-induced immune suppression. J Immunol 186:83–91CrossRefPubMed
15.
Ochando JC, Homma C, Yang Y, Hidalgo A, Garin A, Tacke F et al (2006) Alloantigen-presenting plasmacytoid dendritic cells mediate tolerance to vascularized grafts. Nat Immunol 7:652–662CrossRefPubMed
16.
de Vries VC, Pino-Lagos K, Nowak EC, Bennett KA, Oliva C, Noelle RJ (2011) Mast cells condition dendritic cells to mediate allograft tolerance. Immunity 35:550–561CrossRefPubMedPubMedCentral
17.
Wu KN, Emmons RV, Lisanti MP, Farber JL, Witkiewicz AK (2009) Foxp3-expressing T regulatory cells and mast cells in acute graft-versus-host disease of the skin. Cell Cycle 8:3601–3605CrossRefPubMed
18.
19.
Korngold R, Jameson BA, McDonnell JM, Leighton C, Sutton BJ, Gould HJ et al (1997) Peptide analogs that inhibit IgE-Fc epsilon RI alpha interactions ameliorate the development of lethal graft-versus-host disease. Biol Blood Marrow Transplant 3:187–193PubMed
20.
Murphy GF, Sueki H, Teuscher C, Whitaker D, Korngold R (1994) Role of mast cells in early epithelial target cell injury in experimental acute graft-versus-host disease. J Invest Dermatol 102:451–461CrossRefPubMed
21.
Leveson-Gower DB, Sega EI, Kalesnikoff J, Florek M, Pan Y, Pierini A et al (2013) Mast cells suppress murine GVHD in a mechanism independent of CD4+CD25+ regulatory T cells. Blood 122:3659–3665CrossRefPubMedPubMedCentral
22.
Iwakura Y, Nakae S, Saijo S, Ishigame H (2008) The roles of IL-17A in inflammatory immune responses and host defense against pathogens. Immunol Rev 226:57–79CrossRefPubMed
23.
Torii I, Morikawa S, Harada T, Kitamura Y (1993) Two distinct types of cellular mechanisms in the development of delayed hypersensitivity in mice: requirement of either mast cells or macrophages for elicitation of the response. Immunology 78:482–490PubMedPubMedCentral
24.
Askenase PW, Van Loveren H, Kraeuter-Kops S, Ron Y, Meade R, Theoharides TC et al (1983) Defective elicitation of delayed-type hypersensitivity in W/Wv and SI/SId mast cell-deficient mice. J Immunol 131:2687–2694PubMed
25.
Villa I, Skokos D, Tkaczyk C, Peronet R, David B, Huerre M et al (2001) Capacity of mouse mast cells to prime T cells and to induce specific antibody responses in vivo. Immunology 102:165–172CrossRefPubMedPubMedCentral
26.
Kimber I, Dearman RJ (2002) Allergic contact dermatitis: the cellular effectors. Contact Dermatitis 46:1–5CrossRefPubMed
27.
van Loveren H, Meade R, Askenase PW (1983) An early component of delayed-type hypersensitivity mediated by T cells and mast cells. J Exp Med 157:1604–1617CrossRefPubMed
28.
Geba GP, Ptak W, Anderson GM, Paliwal V, Ratzlaff RE, Levin J et al (1996) Delayed-type hypersensitivity in mast cell-deficient mice: dependence on platelets for expression of contact sensitivity. J Immunol 157:557–565PubMed
29.
Webb EF, Tzimas MN, Newsholme SJ, Griswold DE (1998) Intralesional cytokines in chronic oxazolone-induced contact sensitivity suggest roles for tumor necrosis factor alpha and interleukin-4. J Invest Dermatol 111:86–92CrossRefPubMed
30.
Biedermann T, Kneilling M, Mailhammer R, Maier K, Sander CA, Kollias G et al (2000) Mast cells control neutrophil recruitment during T cell-mediated delayed-type hypersensitivity reactions through tumor necrosis factor and macrophage inflammatory protein 2. J Exp Med 192:1441–1452CrossRefPubMedPubMedCentral
31.
Bryce PJ, Miller ML, Miyajima I, Tsai M, Galli SJ, Oettgen HC (2004) Immune sensitization in the skin is enhanced by antigen-independent effects of IgE. Immunity 20:381–392CrossRefPubMed
32.
Dudeck A, Dudeck J, Scholten J, Petzold A, Surianarayanan S, Kohler A et al (2011) Mast cells are key promoters of contact allergy that mediate the adjuvant effects of haptens. Immunity 34:973–984CrossRefPubMed
33.
Otsuka A, Kubo M, Honda T, Egawa G, Nakajima S, Tanizaki H et al (2011) Requirement of interaction between mast cells and skin dendritic cells to establish contact hypersensitivity. PLoS One 6, e25538CrossRefPubMedPubMedCentral
34.
Thomas WR, Schrader JW (1983) Delayed hypersensitivity in mast-cell-deficient mice. J Immunol 130:2565–2567PubMed
35.
Galli SJ, Hammel I (1984) Unequivocal delayed hypersensitivity in mast cell-deficient and beige mice. Science 226:710–713CrossRefPubMed
36.
Mekori YA, Galli SJ (1985) Undiminished immunologic tolerance to contact sensitivity in mast cell-deficient W/Wv and Sl/Sld mice. J Immunol 135:879–885PubMed
37.
Mekori YA, Weitzman GL, Galli SJ (1985) Reevaluation of reserpine-induced suppression of contact sensitivity. Evidence that reserpine interferes with T lymphocyte function independently of an effect on mast cells. J Exp Med 162:1935–1953CrossRefPubMed
38.
Ha TY, Reed ND, Crowle PK (1986) Immune response potential of mast cell-deficient W/Wv mice. Int Arch Allergy Appl Immunol 80:85–94CrossRefPubMed
39.
Mekori YA, Chang JC, Wershil BK, Galli SJ (1987) Studies of the role of mast cells in contact sensitivity responses. Passive transfer of the reaction into mast cell-deficient mice locally reconstituted with cultured mast cells: effect of reserpine on transfer of the reaction with DNP-specific cloned T cells. Cell Immunol 109:39–52CrossRefPubMed
40.
Williams CM, Galli SJ (2000) Mast cells can amplify airway reactivity and features of chronic inflammation in an asthma model in mice. J Exp Med 192:455–462CrossRefPubMedPubMedCentral
41.
42.
Streilein JW, Taylor JR, Vincek V, Kurimoto I, Richardson J, Tie C et al (1994) Relationship between ultraviolet radiation-induced immunosuppression and carcinogenesis. J Invest Dermatol 103:107S–111SCrossRefPubMed
43.
Hart PH, Grimbaldeston MA, Swift GJ, Jaksic A, Noonan FP, Finlay-Jones JJ (1998) Dermal mast cells determine susceptibility to ultraviolet B-induced systemic suppression of contact hypersensitivity responses in mice. J Exp Med 187:2045–2053CrossRefPubMedPubMedCentral
44.
Grimbaldeston MA, Nakae S, Kalesnikoff J, Tsai M, Galli SJ (2007) Mast cell-derived interleukin 10 limits skin pathology in contact dermatitis and chronic irradiation with ultraviolet B. Nat Immunol 8:1095–1104CrossRefPubMed
45.
Hershko AY, Suzuki R, Charles N, Alvarez-Errico D, Sargent JL, Laurence A et al (2011) Mast cell interleukin-2 production contributes to suppression of chronic allergic dermatitis. Immunity 35:562–571CrossRefPubMedPubMedCentral
46.
47.
Herbert CA, King CM, Ring PC, Holgate ST, Stewart GA, Thompson PJ et al (1995) Augmentation of permeability in the bronchial epithelium by the house dust mite allergen Der p1. Am J Respir Cell Mol Biol 12:369–378CrossRefPubMed
48.
Nakamura T, Hirasawa Y, Takai T, Mitsuishi K, Okuda M, Kato T et al (2006) Reduction of skin barrier function by proteolytic activity of a recombinant house dust mite major allergen Der f1. J Invest Dermatol 126:2719–2723CrossRefPubMed
49.
Wan H, Winton HL, Soeller C, Tovey ER, Gruenert DC, Thompson PJ et al (1999) Der p1 facilitates transepithelial allergen delivery by disruption of tight junctions. J Clin Invest 104:123–133CrossRefPubMedPubMedCentral
50.
Chua KY, Stewart GA, Thomas WR, Simpson RJ, Dilworth RJ, Plozza TM et al (1988) Sequence analysis of cDNA coding for a major house dust mite allergen, Der p1. Homology with cysteine proteases. J Exp Med 167:175–182CrossRefPubMed
51.
Oboki K, Ohno T, Kajiwara N, Arae K, Morita H, Ishii A et al (2010) IL-33 is a crucial amplifier of innate rather than acquired immunity. Proc Natl Acad Sci U S A 107:18581–18586CrossRefPubMedPubMedCentral
52.
Motomura Y, Morita H, Moro K, Nakae S, Artis D, Endo TA et al (2014) Basophil-derived interleukin-4 controls the function of natural helper cells, a member of ILC2s, in lung inflammation. Immunity 40:758–771CrossRefPubMed
53.
Halim TY, Steer CA, Matha L, Gold MJ, Martinez-Gonzalez I, McNagny KM et al (2014) Group 2 innate lymphoid cells are critical for the initiation of adaptive T helper 2 cell-mediated allergic lung inflammation. Immunity 40:425–435CrossRefPubMedPubMedCentral
54.
Ho LH, Ohno T, Oboki K, Kajiwara N, Suto H, Iikura M et al (2007) IL-33 induces IL-13 production by mouse mast cells independently of IgE-FcepsilonRI signals. J Leukoc Biol 82:1481–1490CrossRefPubMed
55.
Iikura M, Suto H, Kajiwara N, Oboki K, Ohno T, Okayama Y et al (2007) IL-33 can promote survival, adhesion and cytokine production in human mast cells. Lab Invest 87:971–978CrossRefPubMed
56.
Suzukawa M, Iikura M, Koketsu R, Nagase H, Tamura C, Komiya A et al (2008) An IL-1 cytokine member, IL-33, induces human basophil activation via its ST2 receptor. J Immunol 181:5981–5989CrossRefPubMed
57.
Morita H, Arae K, Unno H, Miyauchi K, Toyama S, Nambu A et al (2015) An interleukin-33-mast cell-interleukin-2 axis suppresses papain-induced allergic inflammation by promoting regulatory T cell numbers. Immunity 43:175–186CrossRefPubMedPubMedCentral
Metadata
Title
Regulatory roles of mast cells in immune responses
Authors
Hideaki Morita
Hirohisa Saito
Kenji Matsumoto
Susumu Nakae
Publication date
01-09-2016
Publisher
Springer Berlin Heidelberg
Published in
Seminars in Immunopathology / Issue 5/2016
Print ISSN: 1863-2297
Electronic ISSN: 1863-2300
DOI
https://doi.org/10.1007/s00281-016-0566-0

Other articles of this Issue 5/2016

Seminars in Immunopathology 5/2016 Go to the issue

Review

New insights into basophil heterogeneity

Review

IgE and mast cells in host defense against parasites and venoms

Review

Regulation of allergic inflammation by the ectoenzyme E-NPP3 (CD203c) on basophils and mast cells

Review

Transcriptional regulation of mast cell and basophil lineage commitment

Review

Basophil-derived IL-4 plays versatile roles in immunity

Introduction

Basophils and mast cells in immunity and inflammation

ACC 2024 Congress Coverage

Cardiology Video

Highlights from the ACC 2024 Congress

Watch now

Watch official videos from the ACC congress summarizing key highlights from the last year in heart failure, cardiomyopathies, valvular disease, pulmonary vascular disease, and pediatric cardiology.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits